At Week 16 , rilonacept resulted in 70.3 % fewer gout flares per patient ( p < 0.0001 ) , fewer patients with 1 and 2 gout flares ( p < 0.0001 ) , and 64.9 % fewer gout flare days ( p < 0.0001 ) relative to placebo .